Loading clinical trials...
Loading clinical trials...
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects
Conditions
Interventions
ACT-246475
Clopidogrel
+3 more
Locations
1
United States
Biotrial Inc
Newark, New Jersey, United States
Start Date
January 24, 2018
Primary Completion Date
May 20, 2019
Completion Date
May 29, 2019
Last Updated
July 3, 2025
NCT00104325
NCT07470866
NCT07221448
NCT06637865
NCT07388667
NCT07118891
Lead Sponsor
Viatris Innovation GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions